In support of this, the same study found that anti-TIGIT monoclonal antibodies, when used alone, have a dual effect: they boost the antitumor activities of T cells while decreasing IL-32, which in turn inhibits bladder cancer metastasis (153). Here, TIGIT is linked to urinary bladder carcinoma.